Oric Pharmaceuticals, Inc. (ORIC): R&D Expense
$109.82M
Year ended 2025-12-31
$122.36M
Trailing 12 months to 2026-06-30
+21.2%
3-year compound annual growth
+25.0%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $109.82M | -3.7% | 2026-02-23, From 2025-01-01 |
| 2024-12-31 | $114.07M | +33.9% | 2026-02-23, From 2024-01-01 |
| 2023-12-31 | $85.17M | +38.1% | 2025-02-18, From 2023-01-01 |
| 2022-12-31 | $61.68M | +8.5% | 2024-03-11, From 2022-01-01 |
| 2021-12-31 | $56.86M | +58.3% | 2023-03-16, From 2021-01-01 |
| 2020-12-31 | $35.92M | +57.2% | 2022-03-21, From 2020-01-01 |
| 2019-12-31 | $22.84M | +20.1% | 2022-03-21, From 2019-01-01 |
| 2018-12-31 | $19.03M | n/a | 2021-03-23, From 2018-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Oric Pharmaceuticals, Inc. (ORIC) | 2025-12-31 | $109.82M | -3.7% |
| Alumis Inc. (ALMS) | 2025-12-31 | $386.00M | +45.4% |
| Nkarta, Inc. (NKTX) | 2025-12-31 | $90.43M | -6.5% |
| Stoke Therapeutics, Inc. (STOK) | 2025-12-31 | $137.92M | +54.7% |
| Harrow, Inc. (HROW) | 2025-12-31 | $20.94M | +71.2% |
| Tango Therapeutics, Inc. (TNGX) | 2025-12-31 | $132.16M | -8.2% |
| Ironwood Pharmaceuticals Inc (IRWD) | 2025-12-31 | $95.14M | -14.6% |
| Erasca, Inc. (ERAS) | 2025-12-31 | $92.85M | -19.5% |
| MoonLake Immunotherapeutics (MLTX) | 2025-12-31 | $202.86M | +79.9% |
Compare ORIC, ALMS, NKTX, STOK side by side · Screen every company in Pharmaceutical Preparations ↗